AstraZeneca plc (AZN) Ordinary US$0.25
268.00p
(3.62%)
- Add to watchlist
- Create an alert
- This stock can be held in a
268.00p
(3.62%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
268.00p
(3.62%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
Tuesday broker round-up
25 February 2020 13:15
(Sharecast News) - Redrow: Jefferies upgrades to buy with a target price of 981p.
-
AstraZeneca offloads 'Movantik' rights to RedHill Biopharma
25 February 2020 07:30
(Sharecast News) - AstraZeneca has agreed to sublicense its global rights to 'Movantik', or naloxegol, excluding Europe, Canada and Israel, to RedHill Biopharma, it announced on Tuesday.
-
Thursday broker round-up
20 February 2020 13:40
(Sharecast News) - Travis Perkins: Citigroup upgrades to buy with a target price of 1,900p.
-
Director dealings: AstraZeneca director makes share purchase
19 February 2020 16:50
(Sharecast News) - AstraZeneca revealed on Wednesday that non-executive director Michel Demare had acquired 700 ordinary shares in the FTSE 100-listed pharmaceutical giant.
-
Monday broker round-up
17 February 2020 13:05
(Sharecast News) - Hikma Pharmatheuticals: Citigroup downgrades to neutral with a target price of 1,980p.
-
London midday: Stocks steady as some analysts sound hopeful note on coronavirus
14 February 2020 11:27
(Sharecast News) - Stocks have recovered from an early dip after the World Health Organisation said overnight that the spike in coronavirus cases in China on Thursday are not new infections.
-
London open: Stocks little changed as traders reassess coronavirus risks
14 February 2020 08:00
(Sharecast News) - Stocks slipped in early trading as traders grappled with the difficulty of pinpointing how far along China really was in controlling the outbreak of a new coronavirus in the country.
-
AstraZeneca profit falls as costs and writedowns increase
14 February 2020 07:03
(Sharecast News) - AstraZeneca's annual profit fell 14% as rising costs and higher asset writedowns offset sales increases at the pharmaceutical company.
-
Astra reports positive results from stroke, gastric cancer trials
27 January 2020 09:24
(Sharecast News) - AstraZeneca said high-level results from from a phase three trial of its Brilinta drug used in conjunction with aspirin produced a "statistically significant and clinically...
-
AstraZeneca sells hypertension drug rights; Ends Allergan deal
27 January 2020 07:53
(Sharecast News) - AstraZeneca said it had agreed to sell the global commercial rights to a range of hypertension treatments to Atnahs Pharma for up to $390m.
-
Wednesday broker round-up
22 January 2020 12:52
(Sharecast News) - Experian: Morgan Stanley upgrades to overweight with a target price of 2,950p.
-
AstraZeneca clears regulatory hurdles with 'Imfinzi' and 'Lynparza'
20 January 2020 07:19
(Sharecast News) - AstraZeneca announced on Monday that its 'Imfinzi' (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted orphan drug...
Company announcements Announcements
-
Director/PDMR Shareholding
27 February 2020 07:00
AstraZeneca
-
AstraZeneca divests global rights to Movantik
25 February 2020 07:00
AstraZeneca
-
Director/PDMR Shareholding
19 February 2020 07:00
AstraZeneca
-
AZN: Full-year and Q4 2019 results
14 February 2020 07:00
AstraZeneca
-
Total Voting Rights
3 February 2020 15:00
AstraZeneca
-
Enhertu Phase II trial met primary endpoint
27 January 2020 07:00
AstraZeneca
-
Brilinta met primary endpoint in stroke trial
27 January 2020 07:00
AstraZeneca
-
AstraZeneca divests hypertension medicines
27 January 2020 07:00
AstraZeneca
-
AstraZeneca to recover brazikumab (MEDI2070)
27 January 2020 07:00
AstraZeneca
-
Imfinzi, tremelimumab granted ODD in liver cancer
20 January 2020 07:00
AstraZeneca
-
FDA grants Lynparza Priority Review for PROfound
20 January 2020 07:00
AstraZeneca
-
Lynparza granted FDA Priority Review for PAOLA-1
13 January 2020 07:01
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see http://www.DigitalLook.com/newsfeedterms for our terms and conditions.
© Digital Look Ltd 1998-2020. All rights reserved.
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.